Date of submission of the HTAC Recommendation: 11 June 2026
Date of notification to HTAC on the SOH decision: 20 July 2026
The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on gadobutrol (1) 1.0 mmol/mL solution for intravenous (IV) injection, 7.5 mL, in a clear colorless glass vial and (2) 1.0 mmol/mL solution for IV injection, 7.5 mL in a type 1 colorless glass pre-filled syringe (PFS) for use in diagnostic magnetic resonance imaging (MRI) in adults and children through Department of Health (DOH) Department Circular No. 2026-0396 “Inclusion of additional preparations for Gadobutrol in the Philippine National Drug Formulary (PNDF)” dated 18 June 2026.
As a final recommendation, the HTA Council recommends the government financing of the following:
- Gadobutrol 1.0 mmol/mL solution for IV injection, 7.5 mL, in a clear colorless glass vial; and
- Gadobutrol 1.0 mmol/mL solution for IV injection, 7.5 mL in a type 1 colorless glass pre-filled syringe.
For further details, please refer to the documents below: